interest
broadrang
antiinfluenza
monoclon
antibodi
mab
recent
strengthen
identif
antihemagglutinin
ha
mab
endow
heterosubtyp
neutral
activ
use
design
univers
prophylact
therapeut
tool
howev
major
singl
mab
describ
date
bind
neutral
viral
isol
belong
highli
diverg
subtyp
cluster
two
differ
habas
influenza
phylogenet
group
group
includ
among
other
subtyp
group
includ
among
other
subtyp
describ
human
mab
name
capabl
bind
neutral
test
isol
belong
phylogenet
group
includ
subtyp
sever
isol
belong
group
includ
isol
first
period
pandem
therefor
capabl
neutral
isol
belong
subtyp
respons
report
pandem
well
subtyp
pandem
potenti
region
recogn
identifi
stem
region
ha
includ
residu
highli
conserv
among
differ
influenza
subtyp
deep
character
featur
may
repres
use
help
improv
avail
antiinfluenza
therapeut
strategi
provid
new
tool
develop
univers
vaccin
strategi
influenza
one
diseas
shape
human
histori
still
evid
clinic
socioeconom
impact
pandem
rais
sever
major
concern
relat
prophylact
therapeut
measur
avail
antivir
compound
drawback
caus
rapid
emerg
drugresist
isol
requir
prompt
administr
effect
sever
associ
sideeffect
especi
highrisk
categori
includ
children
pregnant
women
addit
vaccin
strategi
expos
annual
risk
ineffect
due
possibl
mismatch
predict
strain
includ
vaccin
actual
circul
moreov
would
engend
prompt
respons
pandem
set
scenario
new
broadrang
univers
antiinfluenza
strategi
requir
particular
would
import
identifi
eventu
elicit
recent
describ
unusu
extrem
broadrang
immun
direct
broadli
conserv
viral
region
differ
common
restrict
immun
direct
highli
variabl
region
number
approach
alreadi
propos
literatur
pivot
role
prophylact
therapeut
field
may
play
avail
broadrang
neutral
human
monoclon
antibodi
mab
allow
identif
human
b
epitop
wide
share
among
differ
influenza
subtyp
inde
accept
antibodi
key
player
natur
protect
influenza
virus
hemagglutinin
ha
main
target
virusneutr
antibodi
respons
howev
although
singl
influenza
infect
provid
lifelong
immun
infect
viru
limit
number
antigen
correl
strain
host
remain
suscept
infect
antigen
drift
variant
due
ha
variabl
ha
major
glycoprotein
influenza
viru
bind
sialic
acid
surfac
cell
globular
head
domain
make
possibl
fusion
viral
envelop
endosom
membran
stalk
region
mainli
form
domain
sixteen
known
subtyp
ha
share
amino
acid
sequenc
ident
cluster
two
distinct
phylogenet
group
group
group
subtyp
group
group
isol
human
particular
subtyp
respons
report
influenza
pandem
outbreak
studi
describ
human
mab
name
capabl
neutral
test
group
isol
well
isol
belong
group
subtyp
capabl
far
caus
pandem
bind
neutral
featur
initi
studi
use
fab
fragment
molecul
produc
e
coli
demonstr
fab
recogn
epitop
stem
region
ha
abl
strongli
neutral
test
strain
well
document
literatur
bival
whole
igg
molecul
may
essenti
featur
biolog
activ
mab
reason
work
evalu
featur
whole
igg
molecul
igg
gener
test
differ
neutral
assay
human
swine
avian
influenza
virus
belong
ha
base
phylogenet
group
encompass
subtyp
respons
describ
pandem
event
result
obtain
show
igg
strongli
neutral
virus
belong
group
well
group
detail
igg
neutral
test
virus
half
maxim
inhibitori
concentr
ic
rang
mgml
virus
ic
rang
mgml
subtyp
isol
ic
mgml
subtyp
strain
ic
mgml
tabl
figur
interestingli
igg
also
potent
neutral
virus
circul
year
ic
rang
mgml
tabl
figur
despit
great
phylogenet
distanc
virus
compar
belong
group
figur
detect
neutral
activ
observ
recent
test
virus
tabl
figur
well
test
isol
screen
random
peptid
phage
display
librari
order
select
peptid
abl
bind
antibodi
could
possibl
indic
region
antibodi
recogn
ha
phagemid
random
peptid
librari
screen
three
round
pan
bind
phage
elut
use
infect
e
coli
elisa
screen
twentyf
posit
clone
sequenc
silico
analysi
perform
use
mimox
pepitop
server
compar
select
peptid
avail
crystal
structur
asouth
id
code
apuerto
hemagglutinin
id
code
studi
allow
identif
sever
possibl
residu
locat
stem
region
ha
potenti
involv
bind
sequenc
number
refer
genbank
access
number
figur
vitro
select
escap
mutant
defin
region
bound
assay
aim
evalu
capabl
induc
escap
mutant
perform
viru
cultur
constant
select
pressur
sever
round
cell
infect
two
escap
mutant
gener
sequenc
analysi
gener
neutral
escap
variant
reveal
two
differ
mutant
carri
singl
amino
acid
mutat
posit
posit
subunit
compar
wild
type
alanin
scan
mutagenesi
studi
basi
result
ha
mutant
carri
alanin
substitut
posit
posit
gener
bind
mutant
evalu
fac
analysi
evidenc
longer
abl
bind
mutat
order
identifi
amino
acid
residu
involv
bind
ha
larg
panel
haalanin
mutant
gener
tabl
fac
analysi
show
bind
ha
decreas
mutant
mutant
figur
mutat
list
tabl
effect
bind
extra
hamut
posit
gener
inde
posit
either
isoleucin
valin
residu
present
differ
isol
belong
either
group
either
group
figur
bind
reduct
mutant
observ
base
result
obtain
ha
mutant
silico
analysi
ha
crystal
structur
carri
amino
acid
residu
alanin
scan
studi
show
influenc
bind
ha
analysi
confirm
residu
identifi
lie
stem
region
ha
belong
subunit
expos
surfac
ha
molecul
figur
similar
approach
follow
also
subtyp
base
result
obtain
studi
four
alanin
mutant
initi
gener
ha
correspond
sequenc
number
figur
figur
tabl
none
alanin
mutat
bound
furthermor
mutant
correspond
posit
number
ha
also
gener
due
presenc
histidin
correspond
posit
virus
increas
bind
mutant
observ
compar
wild
type
ha
order
deeper
investig
absenc
neutral
activ
recent
strain
three
alaninemut
see
tabl
gener
consid
differ
stem
region
recent
neutral
isol
earliest
non
neutral
strain
bind
decreas
observ
ha
mutant
effect
bind
ha
figur
tabl
present
studi
describ
bind
featur
neutral
activ
human
monoclon
antibodi
name
previous
describ
fab
fragment
igg
test
larg
panel
influenza
virus
belong
group
group
subtyp
show
broader
neutral
activ
compar
monoval
molecul
possibl
due
bival
featur
igg
inde
igg
show
figur
neutral
activ
influenza
hemagglutinin
unroot
phylogenet
tree
differ
viral
strain
test
neutral
assay
viral
isol
belong
group
group
present
box
b
box
respect
green
indic
posit
neutral
activ
red
indic
neg
neutral
activ
report
text
abl
neutral
group
strain
also
abl
neutral
isol
span
recombin
ha
asouth
pandem
strain
previous
shown
bound
analog
recombin
ha
acygnu
recogn
data
shown
anew
previous
shown
neutral
fab
fragment
robust
neutral
activ
ic
mgml
test
strain
belong
group
thu
demonstr
epitop
broadli
share
among
group
virus
includ
highli
diverg
subtyp
importantli
show
potent
neutral
activ
also
group
virus
demonstr
epitop
also
present
highli
figur
sequenc
conserv
hemagglutinin
group
subtyp
box
indic
mutat
residu
decreas
bind
mutat
circl
top
indic
percent
bind
ha
alanin
mutant
compar
bind
wildtyp
ha
red
bind
yellow
bind
sequenc
number
base
code
region
genbank
access
number
neutral
activ
strain
highlight
green
red
left
indic
neutral
activ
neutral
activ
respect
recombin
ha
asouth
pandem
strain
previous
shown
bound
analog
recombin
ha
acygnu
recogn
data
shown
anew
previous
shown
neutral
fab
fragment
diverg
subtyp
inde
igg
abl
potent
neutral
strain
circul
ic
mgml
despit
import
phylogenet
distanc
virus
belong
group
figur
neutral
activ
observ
dramat
diverg
isol
test
studi
recent
isol
broad
neutral
activ
highli
diverg
influenza
virus
suggest
epitop
recogn
extrem
conserv
lack
hemagglutin
inhibitori
activ
competit
mous
mab
direct
stem
region
ha
alreadi
suggest
epitop
local
globular
head
share
domain
sever
approach
use
studi
better
defin
region
recogn
screen
phagemid
random
peptid
librari
suggest
bind
stem
region
proxim
viral
membran
interestingli
sequenc
analysi
escap
mutant
gener
select
pressur
identifi
two
residu
local
close
proxim
residu
identifi
peptid
librari
approach
worth
note
none
two
specif
mutat
present
sequenc
avail
public
influenza
databas
http
wwwncbinlmnihgovgenomesflufluhtml
suggest
immun
pressur
residu
poor
region
function
highli
conserv
subtyp
rate
nonconserv
substitut
residu
residu
base
data
ha
mutant
carri
alanin
substitut
posit
posit
gener
fac
analysi
show
lost
capabl
bind
mutat
ha
concord
data
obtain
escap
mutant
residu
posit
also
mutat
valin
aminoacid
larg
present
neutral
isol
figur
inde
confirm
presenc
residu
affect
bind
help
avail
ha
crystal
structur
larger
panel
alanin
mutant
analog
gener
sever
residu
close
identifi
escap
mutant
approach
influenc
interact
ha
figur
restrict
panel
alanin
mutant
gener
ha
confirm
key
role
residu
alreadi
identifi
implic
interact
ha
figur
three
mutant
gener
consid
differ
among
solvent
expos
residu
close
epitopecor
ha
stem
region
recent
neutral
isol
earliest
non
neutral
strain
isol
mutant
partial
affect
bind
one
residu
present
among
neutral
strain
substitut
sever
differ
residu
among
neutral
strain
could
partial
explain
lack
neutral
activ
recent
strain
figur
tabl
overal
result
indic
region
bound
encompass
residu
ha
stem
partial
overlap
bind
region
human
neutral
antibodi
heterosubtip
neutral
activ
limit
influenza
group
virus
group
virus
addit
region
bound
also
partial
share
optim
human
mab
abl
crossneutr
influenza
group
group
virus
importantli
heavi
chain
deriv
rearrang
vh
gene
germlin
alreadi
hypothes
subfamili
wide
share
among
human
mab
heterosubtyp
neutral
activ
limit
group
virus
gene
structur
may
import
confer
broader
heterosubtyp
activ
observ
futur
definit
ha
crystal
structur
comparison
complex
may
help
confirm
possibl
role
conserv
residu
confer
unusu
neutral
properti
although
resolut
crystal
structur
necessari
fine
definit
epitop
sever
import
consider
may
alreadi
made
firstli
previous
specul
presenc
addit
glycosil
site
correspond
present
group
virus
portion
stem
region
virus
reason
lack
activ
mab
heterosubtyp
activ
limit
group
subtyp
present
studi
demonstr
extra
glycosil
site
preclud
bind
neutral
activ
virus
belong
subtyp
figur
test
ha
alanin
mutant
posit
increas
bind
mutant
confirm
key
residu
particularli
import
interact
ha
howev
residu
includ
other
yet
identifi
certainli
play
import
role
bind
ha
shown
lack
activ
observ
recent
isol
test
well
isol
despit
substanti
ident
studi
region
figur
conclus
molecul
describ
paper
singular
human
mab
featur
broad
heterosubtyp
neutral
activ
encompass
group
group
influenza
subtyp
therefor
recogn
broadrang
neutral
human
b
epitop
stem
region
ha
inde
neutral
influenza
virus
belong
subtyp
caus
pandem
human
well
subtyp
pandem
potenti
data
present
may
therefor
crucial
improv
classic
passiv
antiinfluenza
prophylact
therapeut
strategi
also
correct
understand
mechan
lead
vivo
protect
antiinfluenza
immun
therefor
design
effect
vaccin
strategi
inde
sever
pharmacokinet
studi
shown
extrem
low
ic
featur
isol
test
easili
reach
human
system
administr
given
frequent
correl
low
ic
valu
vivo
efficaci
observ
antiinfluenza
mab
could
realli
promis
compound
use
passiv
immun
strategi
importantli
repres
molecular
evid
extrem
wide
unusu
neutral
immun
although
uncommon
may
elicit
cours
natur
infect
potenti
even
newgener
vaccin
approach
focus
epitop
consequ
could
crucial
identif
promis
habas
vaccin
strategi
aim
elicit
broadli
heterosubtyp
protect
immun
similar
one
repres
human
mab
describ
mab
mainli
direct
highli
conserv
domain
whose
use
novel
antiinfluenza
vaccin
approach
wide
investig
howev
demonstr
antibodi
direct
stem
region
characterist
neutral
activ
modul
specif
recogn
epitop
inde
data
present
paper
show
design
innov
approach
ie
socal
headless
approach
import
identifi
also
residu
belong
domain
preserv
elicit
widest
immun
sever
immunogen
usual
obtain
basi
silico
analysi
real
protect
potenti
ascertain
timeconsum
expens
vivo
studi
perspect
could
therefor
extrem
import
reagent
identifi
immunogen
like
stimul
antibodi
similar
broad
heterosubtyp
neutral
activ
constitut
best
candid
vivo
studi
isol
previous
describ
brief
isol
year
old
patient
neg
clinic
histori
infect
influenza
virus
past
ten
year
detect
serum
neutral
titr
half
maxim
inhibitori
dilut
id
two
refer
strain
belong
two
distinct
habas
phylogenet
group
strain
apuerto
group
strain
aport
group
express
e
coli
fab
fragment
defin
featur
obtain
whole
igg
describ
studi
bd
baculogold
system
bd
bioscienc
pharmingen
san
diego
ca
usa
use
briefli
nucleotid
sequenc
codifi
heavi
light
chain
fab
fragment
subclon
baculoviru
express
vector
packfc
progen
biotechnik
gmbh
heidelberg
germani
sf
solut
contain
antibodi
dialyz
pb
concentr
use
amicon
centrifug
filter
devic
millipor
billerica
usa
antibodi
concentr
determin
sdspage
gel
spectrophotometr
measur
nm
antiinfluenza
antibodi
direct
ha
subtyp
name
antihcv
glycoprotein
antibodi
name
produc
purifi
ident
procedur
use
control
experi
follow
refer
strain
test
laboratori
vitasalut
san
raffael
univers
isol
analog
grown
nsk
newborn
swine
kidney
cell
kindli
provid
zooprophylact
institut
brescia
itali
confluenc
cell
mem
supplement
mgml
serumfre
tpcktrypsin
roch
appli
scienc
infect
strain
moi
hour
infect
cell
wash
pb
phosphat
buffer
salin
mem
supplement
mg
ml
trypsin
ad
cell
incub
co
atmospher
cell
observ
daili
monitor
cytopath
effect
usual
hour
supernat
collect
centrifug
rcf
minut
elimin
cell
debri
filter
mm
filter
millipor
billerica
usa
supernat
aliquot
store
cellfre
viru
stock
fluoresc
inhibit
assay
viral
isol
titrat
limit
dilut
method
viral
titer
calcul
reedmuench
formula
neutral
assay
carri
well
plate
use
mdck
cell
well
serial
dilut
mgml
igg
preincub
hour
viru
follow
incub
ml
mix
antibodyviru
ad
cell
incub
anoth
hour
end
incub
cell
wash
pb
ml
mem
tpcktrypsin
mgml
ad
well
cell
incub
hour
wash
pb
fix
permeabil
icecold
ethanol
cell
incub
antiinfluenza
mous
antibodi
argen
shirley
ny
usa
minut
humid
chamber
cell
wash
incub
minut
dark
humid
chamber
fitcconjug
secondari
antibodi
argen
shirley
ny
usa
nuclei
stain
obtain
hoechst
sigma
aldrich
infect
control
without
antibodi
includ
well
neg
control
antibodi
neutral
assay
perform
triplic
repeat
two
differ
session
neutral
activ
antibodi
concentr
express
percentag
reduct
fluoresc
nuclei
compar
nuclei
count
infect
control
nuclei
count
perform
use
ge
healthcar
cell
analyz
autom
epifluoresc
base
microscop
system
neutral
curv
fit
nonlinear
regress
graphpad
prism
softwar
allow
ic
calcul
colorimetr
assay
viral
isol
titrat
establish
work
dilut
produc
foci
form
unit
per
well
tissu
cultur
plate
neutral
assay
carri
well
plate
use
cell
serial
dilut
mgml
igg
preincub
hour
subset
virus
follow
incub
ml
antibodyviru
mix
ad
cell
incub
anoth
hour
co
end
incub
cell
wash
twice
pb
ml
viru
growth
media
contain
mgml
tpck
treat
trypsin
ad
cell
incub
hour
co
wash
pb
fix
permeabil
ice
cold
methanolacet
acid
min
cell
incub
antinp
antibodi
millipor
billerica
usa
minut
cell
wash
incub
addit
minut
mous
hrpconjug
secondari
antibodi
true
blue
chromogen
substrat
kpl
use
count
number
foci
plaqu
reduct
assay
viral
isol
titrat
limit
dilut
method
viral
titr
calcul
reedmuench
formula
viral
titr
also
calcul
plaqu
form
unit
pfu
sixwel
flatbottom
plate
corn
corn
ny
usa
neutral
assay
carri
well
plate
use
mdck
cell
cellswel
two
dilut
mgml
igg
preincub
hour
tcid
viru
follow
incub
ml
virusantibodi
mix
ad
mdck
monolay
plate
incub
hour
co
incub
medium
remov
monolay
wash
twice
pb
two
ml
memagaros
supplement
penicillin
mgml
gibco
invitrogen
carlsbad
ca
usa
streptomycin
mgml
gibco
invitrogen
carlsbad
ca
usa
lglutamin
mm
gibco
invitrogen
carlsbad
ca
usa
trypsin
mgml
roch
appli
scienc
gentli
ad
well
plate
incub
hour
incub
agaros
medium
remov
well
ml
methanolcryst
violet
wv
ad
well
room
temperatur
final
well
wash
tap
water
dri
infect
control
without
antibodi
ad
well
neg
control
mab
neutral
determin
count
pfu
reduct
presenc
antibodi
comparison
infect
control
phagemid
peptid
librari
tm
phage
display
peptid
librari
new
england
biolab
inc
boston
usa
screen
pnsia
fab
fragment
briefli
ng
pnsia
coat
four
well
plate
costar
peptid
librari
amplifi
transform
electrocompet
e
coli
blue
ml
obtain
phage
prepar
incub
pnsia
hour
subsequ
unbound
phage
remov
wash
pb
use
progress
concentr
start
phage
bound
pnsia
elut
use
low
ph
neutral
use
infect
e
coli
blue
subsequ
elisa
screen
ngwell
coat
pnsia
posit
clone
sequenc
use
kitprovid
primer
new
england
biolab
inc
boston
usa
posit
clone
sequenc
silico
analysi
perform
use
mimox
pepitop
server
compar
select
peptid
avail
crystal
structur
asouth
haemagglutinin
experi
perform
confluent
mdck
cell
grow
flask
nunc
rochest
ny
usa
mem
supplement
fb
well
mock
control
dilut
ml
mem
supplement
tpck
trypsin
mgml
obtain
final
concentr
mgml
mgml
mgml
antibodi
tcid
prepar
ml
medium
two
solut
contain
antibodi
viru
mix
order
obtain
final
concentr
mgml
mgml
mgml
mab
final
volum
ml
mix
incub
h
infect
posit
control
viru
without
includ
well
noninfect
cell
two
wash
steril
pb
gibco
invitrogen
carlsbad
ca
usa
ml
neutral
mix
ad
flask
contain
mdck
cell
infect
perform
h
co
absorpt
medium
remov
monolay
wash
twice
steril
pb
ml
mem
supplement
trypsin
mgml
ad
infect
posit
control
noninfect
cell
antibodi
ad
previous
treat
infect
cell
maintain
concentr
use
infect
step
cell
incub
co
regularli
check
hour
presenc
cytopath
effect
cpe
compar
posit
infect
control
treat
infect
cell
supernat
centrifug
rcf
minut
collect
store
viral
stock
titrat
use
infect
new
cell
prepar
increas
possibl
concentr
ten
passag
cell
infect
posit
control
mock
control
compar
infect
cell
select
pressur
strong
cytopath
effect
evid
posit
mock
control
presenc
absenc
cpe
treat
infect
cell
evalu
supernat
collect
centrifug
store
use
perform
full
length
dna
sequenc
influenza
genom
fragment
code
viral
ha
ha
amplifi
previous
describ
use
follow
pcroligonucleotid
ha
amplifi
use
follow
pcroligonucleotid
pcr
product
clone
pcdna
vector
invitrogen
carlsbad
ca
usa
subsequ
alanin
mutant
ha
gener
use
gene
tailor
sitedirect
mutagenesi
system
invitrogen
carlsbad
ca
usa
total
ha
mutant
gener
tabl
bind
activ
assay
use
fulllength
wild
type
mutant
clone
describ
brief
human
epitheli
kidney
hek
cell
atcc
transfect
well
plate
corn
corn
ny
usa
mg
pcdna
vector
contain
ha
nucleotid
sequenc
centrifug
fixat
paraformaldehyd
transfect
cell
incub
minut
room
temperatur
conform
control
control
kindli
provid
ppales
mgml
mgml
addit
isotyp
control
mgml
introduc
well
untransfect
cell
mous
subtyp
monoclon
antibodi
direct
linear
epitop
antiinfluenza
hemagglutinin
genetex
inc
irvin
ca
usa
evalu
transfect
effici
ha
cell
wash
incub
minut
room
temperatur
fitcconjug
antihuman
sigma
aldrich
antimous
argen
shirley
ny
usa
monoclon
antibodi
afterward
cell
wash
analys
fac
fac
data
analyz
use
softwar
weasel
w
walereliza
hall
institut
medic
research
parkvil
victoria
australia
bind
differ
hamut
express
bind
percentag
compar
wildtyp
sequenc
analysi
follow
softwar
packag
use
seqscap
appli
biosystem
clustalx
tobi
gibson
bio
edit
tom
hall
ibi
therapeut
treeview
gubusoft
